Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
---|---|---|---|---|---|---|
Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
Orderbuch | Analysen | |||||
Historisch |
30.04.2025 07:39:33
|
EQS-News: Q1/2025: CompuGroup Medical reports slow start into the year
EQS-News: CompuGroup Medical SE & Co. KGaA
/ Key word(s): Quarterly / Interim Statement/Quarter Results
Q1/2025: CompuGroup Medical reports slow start into the year Koblenz - CompuGroup Medical, one of the world's leading e-health providers, recorded revenues of EUR 286.2 million in the first quarter of 2025, 1 percent higher than the previous year's level (PY: EUR 284.6 million). The organic revenue development was slightly below the prior year (-0.5 percent). At EUR 68.1 million, one-time revenues were 5 percent below the prior year (PY: EUR 71.8 million). Recurring revenues increased by 2 percent to EUR 218.0 million (PY: EUR 212.8 million). The share of recurring revenues increased by 1 percentage point and now accounts for 76 percent of total revenues. In the same period, adjusted EBITDA declined by 16 percent to EUR 51.1 million (PY: EUR 60.7 million). The EBITDA margin stood at 18 percent (PY: 21 percent). CGM continues to invest significantly in innovative products and solutions as well as sales, service and support functions. Expenses for research and development rose year-on-year from EUR 61 million to EUR 68 million in the first quarter of 2025, increasing R&D intensity as percentage of total revenue from 22 percent in the prior year quarter to 24 percent in the first quarter of 2025. New products and solutions developed include CGM one, the fully integrated solution for doctor`s office featuring the AI based phone and documentation assistants, the newly launched CGM TI-Messenger, the AI-supported clinical documentation assistant CGM CDA, and the first cloud-based pharmacy software CGM STELLA. Adjusted earnings per share amounted to EUR 0.35 in the first quarter of 2025 (PY: EUR 0.47). Free cash flow increased by EUR 18.9 million to EUR 78.3 million compared to the prior year’s quarter. Net debt amounted to EUR 702.3 million at the end of March 2025, compared to EUR 772.8 million at the end of December 2024. On April 29, a syndicated loan agreement was signed, consisting of a revolving credit facility of EUR 600 million and a term loan of EUR 150 million, securing CGM's financing until 2030. The total financing funds including the existing financing through a Schuldschein and R&D financing by the European Investment Bank, comprises EUR 1.5 billion, enabling headroom for further growth. In the Ambulatory Information Systems (AIS) segment, revenues in the first quarter of 2025 amounted to EUR 169.3 million, 2 percent below the prior year’s figure of EUR 172.5 million. Recurring revenues stood stable at EUR 131.9 million (PY: EUR 131.5 million). The share of recurring revenues in segment revenues rose from 76 percent to 78 percent. Revenues in the Hospital Information Systems (HIS) segment grew by 5 percent to EUR 81.7 million in the first quarter of 2025 (PY: EUR 77.9 million). Recurring revenues increased by 7 percent to EUR 60.7 million (PY: EUR 56.7 million). The share of recurring revenues rose from 73 percent to 74 percent. In the Pharmacy Information Systems (PCS) segment, revenues in the first quarter of 2025 increased by 3 percent to EUR 35.1 million (PY: EUR 34.3 million). Recurring revenues in the PCS segment increased by 4 percent to EUR 25.5 million (PY: EUR 24.6 million). The share of recurring revenues in segment revenues increased from 72 percent to 73 percent. CGM confirms its guidance for the full year’s financial figures of 2025, with organic revenue growth (adjusted for acquisitions and currency effects) in the low to mid-single digit percentage range year-on-year. Adjusted EBITDA is expected to show slight growth compared to 2024. All three operating segments are expected to achieve at least modest organic revenues growth. The quarterly statement for Q1 2025 is available for download at www.cgm.com/ir-publications.
30.04.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
Language: | English |
Company: | CompuGroup Medical SE & Co. KGaA |
Maria Trost 21 | |
56070 Koblenz | |
Germany | |
Phone: | +49 (0)160 3630362 |
Fax: | +49 (0)261 8000 3200 |
E-mail: | investor@cgm.com |
Internet: | www.cgm.com |
ISIN: | DE000A288904 |
WKN: | A28890 |
Indices: | SDAX, TecDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 2127232 |
End of News | EQS News Service |
|
2127232 30.04.2025 CET/CEST
Nachrichten zu CompuGroup Medical SE & Co. KGaA
13.06.25 |
Zurückhaltung in Frankfurt: TecDAX zum Handelsende mit Abgaben (finanzen.ch) | |
13.06.25 |
TecDAX aktuell: Das macht der TecDAX am Freitagmittag (finanzen.ch) | |
13.06.25 |
Schwacher Handel: TecDAX präsentiert sich zum Start des Freitagshandels schwächer (finanzen.ch) | |
12.06.25 |
Anleger in Frankfurt halten sich zurück: TecDAX am Mittag schwächer (finanzen.ch) | |
11.06.25 |
Aufschläge in Frankfurt: TecDAX beginnt Handel im Plus (finanzen.ch) | |
09.06.25 |
TecDAX-Titel CompuGroup Medical SE-Aktie: So viel Verlust hätte eine CompuGroup Medical SE-Investition von vor 5 Jahren eingebracht (finanzen.ch) | |
06.06.25 |
EQS-News: CompuGroup Medical issues joint reasoned statement recommending shareholders to accept CVC’s public delisting offer (EQS Group) | |
06.06.25 |
EQS-News: CompuGroup Medical veröffentlicht begründete Stellungnahme – und empfiehlt Aktionären die Annahme des öffentlichen Delisting-Erwerbsangebots von CVC (EQS Group) |
Analysen zu CompuGroup Medical SE & Co. KGaA
02.05.25 | CompuGroup Medical Buy | Baader Bank | |
30.04.25 | CompuGroup Medical Buy | Baader Bank | |
11.04.25 | CompuGroup Medical Buy | Baader Bank | |
18.03.25 | CompuGroup Medical Buy | Baader Bank | |
06.03.25 | CompuGroup Medical Buy | Baader Bank |
Abgestürzte Blue Chip Aktien – Wall Street Live mit Tim Schäfer
Tim Schäfer live aus New York – dieses Mal mit einem spannenden Blick auf abgestürzte Blue-Chip-Aktien, bei denen sich ein Einstieg lohnen könnte. Gemeinsam mit David Kunz analysiert Tim prominente Verlierer der letzten Monate, die möglicherweise vor einer Erholung stehen.
Themen im Video:
🔹 Merck & Co. (USA) – Probleme mit Impfstoffen und Patentlaufzeiten
🔹 Pfizer – Wachstumsdruck durch auslaufende Patente
🔹 United Health – Ermittlungen und steigende Gesundheitskosten
🔹 Novo Nordisk – Abnehmspritze, Wettbewerb und Marktkorrektur
🔹 Nike – Konsumflaute und neue Konkurrenz
🔹 Estée Lauder – Kursabsturz, China-Schwäche und Hoffnung auf Turnaround
🔹 Campbell Soup – Value-Aktie mit attraktiver Dividende
🔹 Regeneron – Erfolgreiche Gründerstory mit Herausforderungen
👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
SMI und DAX gehen tiefrot ins Wochenende -- Wall Street beendet Handel leichter -- Asiens Börsen letztlich im MinusDer heimische sowie der deutsche Aktienmarkt präsentierten sich zum Wochenschluss deutlich leichter. Die Wall Street bewegte sich am letzten Handelstag der Woche abwärts. An den asiatischen Börsen waren am Freitag ebenso Abschläge zu sehen.
finanzen.net News
Datum | Titel |
---|---|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |